Floatz logo

Cart-19 Cells

CD19 Positive Malignant B-cell Leukemia and Lymphoma

RenJi HospitalCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the CD19 Positive Malignant B-cell Leukemia and Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
RenJi Hospital
Phase 1CC
Cyclophosphamide
RenJi Hospital
Phase 1CC

Same molecule, other indications

Cart-19 Cells is also rated in:

B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
B
Indicative ·
61 / 100
View asset →
Burkitt lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →